Katsoulaki Eleftheria-Emmanouela, Dimopoulos Dimitrios, Hadjipavlou-Litina Dimitra
Laboratory of Pharmaceutical Chemistry, School of Pharmacy, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Pharmaceuticals (Basel). 2025 Jun 1;18(6):831. doi: 10.3390/ph18060831.
Multitarget drugs are molecules with the ability to act simultaneously on different targets at the same time, and they have been evaluated in the last decade as a powerful tool in the development of promising therapeutics for neurodegenerative diseases. This is very useful for multifactorial diseases such as Alzheimer's, Parkinson's, and Huntington's diseases, a group of neurological disorders that induce neurodegeneration and neuroinflammation. Successful drug design for multifactorial diseases depends on an interdisciplinary and collaborative approach. The complexity of the above pathologies has clearly demonstrated that such single-target drugs are inadequate to achieve a successful therapeutic result. Furthermore, molecules hitting more than one biological target exhibit also a safer profile. In this review, we present a comprehensive knowledge of recent research on multitarget synthetic approaches to confront Alzheimer's, Parkinson's, and Huntington's neurodegenerative diseases.
多靶点药物是能够同时作用于不同靶点的分子，在过去十年中，它们被视为开发神经退行性疾病有前景疗法的有力工具。这对于诸如阿尔茨海默病、帕金森病和亨廷顿病等多因素疾病非常有用，这些神经疾病会引发神经退行性变和神经炎症。针对多因素疾病的成功药物设计依赖于跨学科的协作方法。上述病症的复杂性清楚地表明，此类单靶点药物不足以取得成功的治疗效果。此外，作用于多个生物靶点的分子也具有更安全的特性。在本综述中，我们全面介绍了近期关于应对阿尔茨海默病、帕金森病和亨廷顿病神经退行性疾病的多靶点合成方法的研究。
